Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (03) : 205-212     DOI: 10.3971/j.issn.1000-8578.2022.21.0716
|
Effects of Chemoradiotherapy Versus Chemotherapy Alone on Survival of Patients with Primary Mediastinal Large B-cell Lymphoma
FAN Bingjie, CHANG Yu, LIU Xiyang, ZHANG Mingzhi, ZHANG Lei
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China
Download: PDF(6018 KB)   ( 45 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Objective To explore the prognostic factors of primary mediastinal large B-cell lymphoma (PMBCL) and the effects of chemoradiotherapy versus chemotherapy alone on patients’ prognosis before and after rituximab era. Methods We extracted the data of PMBCL patients diagnosed from 2001 to 2015 from SEER database. SEER Stat software was used to calculate the incidence rate. Kaplan-Meier method and Cox regression model were used to analyze the impact of various clinical variables on prognosis. Results We included 635 patients with PMBCL. Multivariate Cox regression analysis showed that age, stage and chemotherapy were independent prognostic factors. Kaplan-Meier survival analysis showed that OS of the patients receiving chemotherapy only in 2006-2015 was significantly better than that in 2001-2005 (χ 2=10.002, P=0.002). The patients who received chemoradiotherapy had better OS than those who received chemotherapy alone from 2001 to 2005. The OS and DSS of patients receiving chemoradiotherapy were not significantly different from those of chemotherapy alone from 2006 to 2015. Conclusion The application of rituximab improves the long-term survival of PMBCL patients. The prognosis of patients who received chemoradiotherapy is comparable to that of chemotherapy alone from 2006 to 2015.
Keywords Primary mediastinal large B-cell lymphoma      Radiochemotherapy      Chemotherapy      SEER database      Survival analysis     
ZTFLH:  733  
Fund:National Natural Science Foundation of China Youth Fund (No. 82000204)
Issue Date: 17 March 2022
 Cite this article:   
FAN Bingjie,CHANG Yu,LIU Xiyang, et al. Effects of Chemoradiotherapy Versus Chemotherapy Alone on Survival of Patients with Primary Mediastinal Large B-cell Lymphoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(03): 205-212.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.21.0716
http://www.zlfzyj.com/EN/Y2022/V49/I03/205
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
FAN Bingjie
CHANG Yu
LIU Xiyang
ZHANG Mingzhi
ZHANG Lei
[1] Mottok A, Wright G, Rosenwald A, et al. Molecular classification
of primary mediastinallarge B-cell lymphoma using routinely
available tissue specimens[J]. Blood, 2018, 132(22): 2401-2405.
[2] Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision
of the World Health Organization classification of lymphoid
neoplasms[J]. Blood, 2016, 127(20): 2375-2390.
[3] Ahmed Z, Afridi SS, Shahid Z, et al. Primary Mediastinal B-Cell
Lymphoma: A2021Updateon Genetics, Diagnosis, and Novel
Therapeutics[J]. Clin Lymphoma Myeloma Leuk, 2021, 21(11):
e865-e875.
[4] Martelli M, Ferreri A, Di Rocco A, et al. Primary mediastinal
large B-cell lymphoma[J]. Crit Rev Oncol Hematol, 2017, 113:
318-327.
[5] Zhou H, Xu-Monette ZY, Xiao L, et al. Prognostic factors,
therapeutic approaches, and distinct immunobiologic features in
patients with primary mediastinal large B-cell lymphoma on longterm
follow-up[J]. Blood Cancer J, 2020, 10(5): 49.
[6] Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH rituximab therapy in primary mediastinal B-cell lymphoma[J]. N Engl J Med, 2013, 368(15): 1408-1416.
[7] Wilson WH, Jung SH, Porcu P, et al. A Cancer and Leukemia
Group B multi-center study of DA-EPOCH-rituximab in untreated
diffuse large B-cell lymphoma with analysis of outcome by
molecular subtype[J]. Haematologica, 2012, 97(5): 758-765.
[8] Dunleavy K, Wilson WH. Primary mediastinal B-cell lymphoma
and mediastinal gray zone lymphoma: do they require a unique
therapeutic approach?[J]. Blood, 2015, 125(1): 33-39.
[9] Goldschmidt N, Kleinstern G, Orevi M, et al. Favorable outcome
of primary mediastinallarge B-cell lymphoma patients treated
with sequential RCHOP-RICE regimen without radiotherapy[J].
Cancer Chemother Pharmacol, 2016, 77(5): 1053-1060.
[10] Bhakta N, Liu Q, Yeo F, et al. Cumulative burden of cardiovascular
morbidity in paediatric, adolescent, and young adult survivors
of Hodgkin's lymphoma: an analysis from the St Jude Lifetime
Cohort Study[J]. Lancet Oncol, 2016, 17(9): 1325-1334.
[11] Hamlin PA, Satram-Hoang S, Reyes C, et al. Treatment patterns
and comparative effectiveness in elderly diffuse large B-cell
lymphoma patients: a surveillance, epidemiology, and end resultsmedicare
analysis[J]. Oncologist, 2014, 19(12): 1249-1257.
[12] Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel
CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma[J]. N
Engl J Med, 2017, 377(26): 2531-2544.
[13] Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety
and activity of axicabtagene ciloleucel in refractory large B-cell
lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2
trial[J]. Lancet Oncol, 2019, 20(1): 31-42.
[14] Vardhana S, Hamlin PA, Yang J, et al. Outcomes of Relapsed
and Refractory Primary Mediastinal (Thymic) Large B Cell
Lymphoma Treated with Second-Line Therapy and Intent to
Transplant[J]. Biol Blood Marrow Transplant, 2018, 24(10):
2133-2138.
[15] Giri S, Bhatt VR, Pathak R, et al. Role of radiation therapy in
primary mediastinal large B-cell lymphoma in rituximab era: A
US population-based analysis[J]. Am J Hematol, 2015, 90(11):
1052-1054.
[16] Vassilakopoulos TP, Pangalis GA, Katsigiannis A, et al. Rituximab,
cyclophosphamide,doxorubicin, vincristine, and prednisone
with or without radiotherapy in primary mediastinal large B-cell
lymphoma: the emerging standard of care[J]. Oncologist, 2012,
17(2): 239-249.
[17] Filippi AR, Piva C, Giunta F, et al. Radiation therapy in primary
mediastinal B-cell lymphoma with positron emission tomography
positivity after rituximab chemotherapy[J]. Int J Radiat Oncol
Biol Phys, 2013, 87(2): 311-316.
[18] Messmer M, Tsai HL, Varadhan R, et al. R-CHOP without
radiation in frontline management of primary mediastinal B-cell
lymphoma[J]. Leuk Lymphoma, 2019, 60(5): 1261-1265.
[19] Hayden AR, Tonseth P, Lee DG, et al. Outcome of primary
mediastinal large B-cell lymphoma using R-CHOP: impact of a
PET-adapted approach[J]. Blood, 2020, 136(24): 2803-2811.
[20] Vassilakopoulos TP, Papageorgiou SG, Angelopoulou MK, et
al. Positron emission tomography after response to rituximab-
CHOP in primary mediastinal large B-cell lymphoma: impact
on outcomes and radiotherapy strategies[J]. Ann Hematol, 2021,
100(9): 2279-2292.
[21] Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in
Relapsed or Refractory Primary Mediastinal Large B-Cell
Lymphoma[J]. J Clin Oncol, 2019, 37(34): 3291-3299.
[22] Zinzani PL, Santoro A, Gritti G, et al. Nivolumab Combined
With Brentuximab Vedotin for Relapsed/Refractory Primary
Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From
the Phase Ⅱ CheckMate 436 Study[J]. J Clin Oncol, 2019,
37(33): 3081-3089.
[23] Hatic H, Sampat D, Goyal G. Immune checkpoint inhibitors in
lymphoma: challenges and opportunities[J]. Ann Transl Med,
2021, 9(12): 1037.
Related articles from Frontiers Journals
[1] MAO Wanli, RAN Li, LI Jiehui, LI Fenghu, CHANG Jianying, MU Junyu, MEI Fan, HU Lili, DU Yanjun, TIAN Xue, QIN Yao, YIN Shuishui. Predictive Value of CD44v6 and EGFR Expression in Neoadjuvant Chemotherapy Sensitivity of Stage Ⅱ-Ⅲ Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 937-943.
[2] CHEN Zegang, WANG Yongbing, OU Tao. Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 982-986.
[3] SUI Daxing, WANG Xueying, ZHANG Jiaxin. A New N-staging System for Predicting Postoperative Survival of M0 Stage Inflammatory Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 799-805.
[4] KANG Yikun, YUAN Peng. Advances in Treatment of Triple Negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 812-819.
[5] WEI Zongjie, KUANG Youlin, CHEN Yong, WANG Lu, CHEN Xiao, GOU Xin. Efficacy and Adverse Reaction of Tislelizumab Combined with Chemotherapy on Urothelial Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 698-702.
[6] XIE Zhanghong, HUA Qingquan. Research Progress of Ferroptosis in Head and Neck Squamous Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 282-287.
[7] LUO Wenqing, LI Yuanqi, YE Fei, LI Qiangming, ZHANG Guoqing, LI Xiangnan. Construction and Validation of A Nomogram Prognostic Model for Patients with Lung Adenocarcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(03): 197-204.
[8] YANG Hao, MEI Tonghua. Effect of Lymph Node Metastasis on Prognosis of Small Cell Lung Cancer with M1a Disease: A Study Based on SEER database[J]. Cancer Research on Prevention and Treatment, 2022, 49(02): 116-122.
[9] LIU Zhenghao, YANG Chunguang, HU Zhiquan. Research Progress on Immunoregulation of Chemotherapeutic Agents[J]. Cancer Research on Prevention and Treatment, 2022, 49(01): 72-77.
[10] LU Mei, YANG Xiaojuan, ZOU Jieya, GUO Rong, WANG Xin, ZHANG Qian, DENG Xuepeng, TAO Jianfen, NIE Jianyun, YANG Zhuangqing. Efficacy Prediction Model for Neoadjuvant Chemotherapy on Breast Cancer Based on Differential Genes Expression[J]. Cancer Research on Prevention and Treatment, 2021, 48(12): 1071-1077.
[11] SUN Chongyuan, ZHAO Dongbing. Characteristics and Risk Factors of Postoperative Complications in Gastric Cancer Patients Treated with Neoadjuvant Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2021, 48(11): 1046-1052.
[12] LIU Ying, XIE Bin, WANG Meng, LI Yiran, YAN Wenjin, XU Xingxiang, MIN Lingfeng. A Survival Prediction Model of Pulmonary Sarcomatoid Carcinoma Based on SEER Database[J]. Cancer Research on Prevention and Treatment, 2021, 48(09): 853-858.
[13] ?WU Zhaoyang, WANG Shenglin, SHEN Rongkai, CHEN Fei, LIN Jianhua, ZHU Xia, ZHANG Zhenzhen. Association Between Osteogenic Differentiation in Soft Tissue Lump and Clinicopathological Characteristics of Osteosarcoma Patients[J]. Cancer Research on Prevention and Treatment, 2021, 48(09): 859-863.
[14] HE Puyi, LI Xuemei, WANG Yunpeng, XU Bo, WANG Haiyun, ZHANG Jing, PU Weigao, CHEN Hao. Advances in Application of PDT Combined with Multiple Therapies on Unresectable Extrahepatic Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(09): 893-897.
[15] PAN Zhongmian, CHEN Qi, LI Li. Prognosis of Stage ⅠB-ⅡA Cervical Squamous Cell Carcinoma Patients with Intermediate Risk Factors Treated with Adjuvant Chemotherapy Versus Concurrent Chemoradiotherapy: A Prospective Randomized Controlled Trial[J]. Cancer Research on Prevention and Treatment, 2021, 48(07): 714-718.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed